Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 661 to 675 of 817 results for mental health

  1. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  2. What are the risks that predict the development of blood-borne virus infections in people with complex psychosis in the UK?

    explanatory notes(if applicable) Care and treatment for physical health conditions (recommendations 1.10.18 and 1.10.19) The...

  3. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  4. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  5. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  6. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

  7. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  8. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.

  9. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  10. Extended access to social care services:- What is the clinical and cost effectiveness of providing extended access to social care services, for example during early mornings and evenings, and 7 days a week?

    circumstances. This is based on the definition of social care in section 65 of the Health andSocial Care Act 2012.At present access to...

  11. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

  12. Rheumatoid arthritis in adults: management (NG100)

    This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.

  13. Multiple pregnancy: twin and triplet pregnancies (QS46)

    This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.

  14. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

  15. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.